New hope for stubborn arthritis? drug combo trial seeks better control
NCT ID NCT05306353
Summary
This study tested whether adding a new drug called VIB4920 to standard arthritis medication (TNF inhibitors) could better control rheumatoid arthritis in adults whose current treatment wasn't working well enough. It was a Phase 2 trial that planned to enroll 104 participants but was terminated early after enrolling only 2 people. The goal was to see if the combination reduced disease activity more effectively than the standard treatment alone.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RHEUMATOID ARTHRITIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Brigham & Women's Hospital: Department of Medicine, Rheumatology, Immunology
Boston, Massachusetts, 02215, United States
-
Duke University Medical Center: Division of Rheumatology and Immunology
Durham, North Carolina, 27710, United States
-
University of California San Francisco School of Medicine: Lupus Clinic and Rheumatology Clinical Research Center
San Francisco, California, 94110, United States
-
University of Colorado School of Medicine: Division of Rheumatology
Aurora, Colorado, 80045, United States
-
University of Michigan Health System: Department of Internal Medicine, Division of Rheumatology
Ann Arbor, Michigan, 48109, United States
Conditions
Explore the condition pages connected to this study.